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Information about predictors of decline in pulmonary function (forced expiratory volume in 1 second [FEV1]) or health-related quality of life
(HRQoL) in patients with asthma or (chronic obstructive pulmonary disease [COPD]) might help to determine those who need additional care. A
2-year prospective cohort study was conducted among 380 asthma and 120 COPD patients. In both asthma and COPD patients, a 2-year change in
FEV1 was only weakly associated with a 2-year change in HRQoL (r = .0.19 and 0.24, respectively). In both groups, older age, living in an urban
environment, and a lower peak expiratory flow rate (PEFR) at baseline were associated with a decline in FEV1. Additional predictors of FEV1 decline
were greater body weight, less chronic cough or sputum production, and less respiratory symptoms in asthma patients and current smoking in COPD
patients. A decline in HRQoL was associated with older age, non-compliance with medication, more dyspnea, and a lower PEFR in asthma patients
and with male gender, lower education, lower body weight, more dyspnea, and more respiratory symptoms in COPD patients. Our results show that
FEV1 and HRQoL appear to represent different disease aspects influenced by different predictors.
Keywords asthma, chronic obstructive pulmonary disease (COPD), health-related quality of life, pulmonary function, longitudinal study
INTRODUCTION
Pulmonary function and health-related quality of life
(HRQoL) are both independently of great importance in the
management of asthma and chronic obstructive pulmonary
disease (COPD) (1–4). Assessing the airway obstruction
by measuring the forced expiratory volume in one second
(FEV1) was, until recently, the most common way to assess
disease severity, response to therapy, and (short-term) prog-
nosis in asthma and COPD patients (4). Yet, the use of FEV1
as the single best evaluation parameter has been questioned
(5–9). Therefore, in the past decade, HRQoL has become an
established parameter to assess a patient’s subjective experi-
ence of the impact of disease (4, 10). Since there is no strong
association between FEV1 and HRQoL, both measures seem
to highlight different aspects of the disease and therefore pro-
vide complementary information on the actual severity of the
disease (1–4).
Until now, most studies on FEV1 or HRQoL were based
on cross-sectional research. Longitudinal research has mainly
focused on evaluating the effectiveness of treatment. Conse-
quently, information on the predictors of changes in FEV1
or HRQoL evaluated in non-experimental settings is scarce.
Information on the variables used in routine follow-up care,
which may predict changes in FEV1 or HRQoL, might help
physicians to distinguish between patients who need addi-
tional attention (11). The objectives of this study were (1) to
∗Corresponding author: Arlette E. Hesselink, Ph.D., GG&GD Amster-
dam, Cluster EDG, P.O. Box 2200, 1000 CC Amsterdam, The Netherlands;
E-mail: A.E.Hesselink@AMC.UVA.nl
study the course of FEV1 and HRQoL over a period of 2 years
and (2) to identify predictors of changes in FEV1 and HRQoL
over time. Chronic airway obstruction is a common charac-
teristic of asthma and COPD. However, asthma and COPD
are different diseases with a different clinical manifestation,
and thus were analyzed separately (12).
METHODS
Design and Study Population
Patients enrolled in a cohort study received three annual
examinations, including a pulmonary function test, a face-to-
face interview, and a written questionnaire. All examinations
were performed between 1995 and 2000 by well-trained re-
search assistants. A detailed description of patients and meth-
ods can be found elsewhere (1). Briefly, 31 general practition-
ers (GPs) from 25 practices in two rural regions in the east
and northwest and one urban region in the west of the Nether-
lands selected all patients who met the following inclusion
criteria: a clinical diagnosis of asthma, COPD, or mixed dis-
ease (asthma with persisting airway obstruction), age 16 to
75 years, primarily treated in the general practice and ab-
sence of other specific pulmonary or terminal diseases. The
GPs selected 2,047 patients, of whom 1,325 (65%) partici-
pated. Non-responders were generally younger and more of-
ten male than responders (p < 0.01). Of the responders only
those who stated at their initial interview that they currently
used asthma or COPD medication and experienced disease
symptoms such as coughing and sputum production or dysp-
nea were included in the study (n = 867). The final criterion
was that they had attended at least one follow-up examina-
tion. Of the 1,325 responders, 539 (41%) met all inclusion
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criteria and were included in the present prospective cohort
study.
Outcome Measures
The outcome variables of FEV1 and HRQoL were mea-
sured at baseline and after 1 and 2 years. All assessments took
place during the same period each year. FEV1 was measured
according to the American Thorax Society (ATS) criteria us-
ing a handheld spirometer (SpiroSense; Tamarac Systems,
Denver, COL, USA) in the west and east of the county, and
a dry rolling seal spirometer (MasterScreen CS/FRC; Jaeger
Toennies, Hoechberg, Germany) in the northwest (13). Pa-
tients were instructed not to use bronchodilators on the day
that their pulmonary function was assessed. FEV1 was ex-
pressed as a percentage of the predicted FEV1 (FEV1%pred).
The predicted FEV1 was based on gender, height, and age us-
ing the predicted adult standards of European Community for
Coal and Steel (14).
HRQoL was measured using the Quality of Life in Res-
piratory Illness Questionnaire, which was filled out at the
respondent’s home (15). This questionnaire was specifically
developed and validated for patients with mild to moderate
asthma or COPD and covers a broad range of aspects of daily
life. It contains 55 items divided into 7 subscales: breath-
ing problems, physical problems, emotions, general activity,
situation triggers, daily and domestic activities, and social ac-
tivities. Each item assesses, on a 7-point scale, the extent to
which the patient is troubled due to pulmonary complaints:
(1) “no trouble at all” to (7) “very much trouble.” A score
is calculated for each subscale separately, after which a to-
tal score is computed (possible range 7–49). Less than 50%
missing items were allowed per subscale and were substi-
tuted, and one missing subscale was allowed for the calcu-
lation of the overall HRQoL score. At baseline, Cronbach’s
alpha varied from 0.84 to 0.92 for the subscales and was 0.96
for the overall scale, which confirms the internal consistency
of this questionnaire. The scale was transformed in such a
way that a low score indicated a poor HRQoL.
Predictors
The GPs provided information about age (years) and gen-
der. Information about the level of education (classified as
low, medium, or high, depending on the duration of the ed-
ucation), co-morbidity (if a patient had one or more other
chronic conditions), medication (categorized according to the
step-care therapy rules) (16), duration of disease (years), and
hyperreactivity (sensitive to more than four of eight triggers
such as smoke, temperature changes, humidity, stress, and
physical activity) were gathered during the face-to-face inter-
view with the patient. In addition, patients were asked about
their degree of dyspnea according to the Medical Research
Council (MRC) questionnaire (scale from 0 = no dyspnea
to 4 = dyspnea when standing still), wheezing (never, ever,
or most days and nights), and chronic cough or sputum pro-
duction (present, not present). A blood sample was taken
for the assessment of allergy, which was defined as present
if a patient had a positive Phadiathop test (Pharmacia AB,
Uppsala, Sweden) (17). In a written questionnaire, informa-
tion was gathered about compliance with anti-inflammatory
agents using a three-item checklist and on smoking behavior
(never, former, current). In the 2 weeks after this baseline
assessment the patients filled out a diary chart monitoring a
morning and evening peakflow expiratory flow rate (PEFR)
measured with a peak flow meter. Variability in PEFR was
expressed as the lowest morning PEFR measured in one day,
expressed as a percentage of the predicted PEFR (18). On the
diary charts the patients also recorded the use of bronchodila-
tors and whether the past day or night had been disturbed by
respiratory symptoms. In case of missing data on PEFR, use
of bronchodilators, or respiratory symptoms, data were ex-
trapolated if valid data were provided for at least 10 days
(1).
Diagnosis of Asthma, COPD or Mixed Disease
The diagnosis of the disease was based on baseline pul-
monary function, according to the guidelines issued by the
Dutch College of General Practitioners (1, 19). Asthma
was defined as: (1) pre (before use of a bronchodilator)
FEV1%pred ≥80% or (2) a combination of preFEV1%pred
<80%, a reversible obstruction (≥9% increase of FEV1 10
minutes after admission of bronchodilator), and a post (after
use of a bronchodilator) FEV1%pred ≥80%. COPD was
defined as: preFEV1%pred <80% combined with an irre-
versible obstruction (increase FEV1 10 minutes after admis-
sion of bronchodilator <9% of predicted). Mixed disease was
defined as preFEV1%pred <80%, a reversible obstruction,
and a postFEV1%pred <80%.
Statistical Analyses
Data were analyzed using SPSS 9.0 software (Chicago,
IL, USA) and MlwiN (Centre for Multilevil Modeling 2002,
version 1.10.0007). Of the 539 patients who met all inclu-
sion criteria, 39 patients were diagnosed as having mixed
disease; since this number is too small for the analyses used
in this study, these patients were excluded from further anal-
yses. All analyses were performed for asthma and COPD
separately. Descriptive statistics, including Chi-square tests,
t tests, or Mann Whitney U-tests, were used to compare base-
line characteristics between asthma and COPD patients. In
the northwest region, an education program was provided for
a subsample of patients, but this program had no effect on
HRQoL or on any other variables included in this study (20).
Nevertheless, the intervention was introduced in all analyses
as a covariate.
To study change in FEV1 and HRQoL over time, multiple
linear multilevel regression analyses were applied, conducted
with time as categorical predictor variable. Pearson’s correla-
tion coefficients (r) were calculated to predict the correlation
between FEV1 and HRQoL at baseline and between changes
in FEV1 and HRQoL over time. To investigate the predictive
value of different baseline patient and disease characteris-
tics on changes in FEV1 and HRQoL over time, multivari-
ate linear multilevel regression analyses were also applied,
including the baseline value of FEV1 or HRQoL as a co-
variate. Multilevel analyses were used to account for corre-
lations within patients. Furthermore, patients were clustered
within one general practice. Therefore, analyses were per-
formed with a three-level structure (time, patient, and GP).
First, for all potential predictors, the univariate association
with the outcome measure was examined. Each variable with
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an association of p < 0.20 was entered in the multivariate
model. Finally, the best predictive model was constructed,
using a (manual) backward selection method, deleting those
variables that had the weakest association with the outcome
(p > 0.10). Separate models were constructed for the two
outcome measures FEV1 and HRQOL and for asthma and
COPD.
RESULTS
In Table 1, patient characteristics are presented separately
for asthma and COPD patients. As expected, compared to
asthma, significantly more COPD, patients were male, were
older, had a lower level of education, more often had comor-
bidities, were more often current or former smokers, were less
often allergic or hyperreactive, and had more severe dyspnea,
more frequent respiratory symptoms, and a lower PEFR. In
addition, patients with more COPD often used medication,
TABLE 1.—Baseline characteristics of patients.
Characteristics
Asthma
(n = 380)
COPD
(n = 120) p value
Gender (men) 130 (34%) 70 (58%) <0.01
Age, years (SD) 45.0 (14.3) 57.5 (13.4) <0.01
Educational level
Low 188 (49%) 83 (69%) <0.01
Medium 124 (33%) 25 (21%)
High 68 (18%) 12 (10%)
Body weight, kgs (SD) 78.1 (15.3) 75.7 (13.8) 0.13
Region of living
West (urban) 172 (45%) 56 (47%) 0.09
East (suburban) 63 (17%) 29 (24%)
North-west (suburban) 145 (38%) 35 (29%)
Comorbidity 144 (38%) 58 (48.3%) 0.04
Smoking
Never 169 (45%) 25 (21%) <0.01
Former 115 (31%) 49 (42%)
Current 89 (24%) 44 (37%)
Medication1
Step 1 87 (23%) 13 (11%) <0.01
Step 2 229 (60%) 60 (50%)
Step 3 and 4 64 (17%) 47 (39%)
Compliance
Compliant 141 (37%) 17 (14%) 0.01
Not compliant 130 (34%) 57 (48%)
Missing 109 (29%) 46 (38%)
Duration of disease (years) 19.9 (15) 25.8 (21) <0.01
Allergy test
Negative 152 (40%) 72 (60%) <0.01
Positive 204 (54%) 41 (16%)
Missing 24 (6%) 7 (6%)
Hyperreactivity 259 (70%) 70 (60%) 0.05
Dyspnea-grade,2 score 0 to 4 (SD) 1.1 (1.2) 1.5 (1.2) 0.01
Wheeze
Never 28 (8%) 14 (12%) 0.24
Ever 284 (75%) 81 (68%)
Most days and nights 67 (18%) 25 (21%)
Chronic cough or sputum production
present
192 (51%) 64 (53%) 0.59
Days or nights disturbed by respiratory
complaints,3 number (SD)
1.6 (2.6) 2.6 (3.7) <0.01
Use of β-agonists,3 number (SD) 7.1 (7.1) 10.7 (5.4) <0.01
PEFR (low [morning]%
predicted),3% (SD)
81.7 (17.8) 57.6 (17.1) <0.01
FEV1%pred,4% (SD) 95.1 (15.) 60.6 (16.) <0.01
HRQoL,3 (score 7 to 49 (SD) 40.6 (6.1) 39.2 (6.2) 0.02
1Stepped care therapy: step 1, β-agonists only; step 2, low or moderate dose cortico-
steroids or cromoglycerine; step 3, moderate dose corticosteroids or cromoglycine and long-
acting β-agonists; and step 4, high dose corticosteroids or cromoglycine with long-acting
β-agonists.
2Higher score indicates more severe dyspnea.
3Measured by day chart over a period of 14 days.
4Higher score indicates better FEV1%pred and HRQoL.
were less compliant with treatment, had their disease longer,
and used brochodilators more often than patients with asthma.
Furthermore, COPD patients had a poorer FEV1 and a poorer
HRQoL.
Changes in FEV1 and HRQoL During Follow-Up
Changes in FEV1 and HRQoL after 1 and 2 years, com-
pared to baseline, can be seen in Figures 1 and 2. In asthma
patients, the mean change in FEV1 after 1 year (mean change
−0.07%, 95%CI −1.04 to 0.91) and after 2 years (mean
change −0.01%, 95%CI −1.05 to 1.03) was small. The to-
tal score for HRQoL and all subscales improved slightly in
the first year (mean change 0.51, 95%CI 0.03 to 0.98) and
decreased slightly in the second year (mean change 0.37,
95%CI −0.14 to 0.89). In patients with COPD a consider-
able decline in FEV1 was noted after 1 year (mean change
−2.96%, 95%CI −4.48 to −1.45) and, after 2 years (mean
change −3.17%, 95%CI −4.82 to −1.52). For HRQoL, a
mixture of positive and negative changes on the subscales
was seen after 1 year in COPD patients, resulting in a small
nonsignificant improvement in the total HRQoL scale (mean
change 0.19%, 95%CI −0.59 to 0.97). After 2 years the total
HRQoL (mean change −0.89, 95%CI −1.74 to −0.04) and
all subscales declined. Despite the small mean changes in
FEV1 and HRQoL, there was sufficient variation in change
on both outcome measures across patients to continue with
the analyses of predictors of change.
The correlation between FEV1 and HRQoL at baseline
was nonsignificant in both asthma (r = 0.07) and COPD
(r = 0.11) patients. The correlation between the changes in
FEV1 and HRQoL over 2 years was statistically significant,
but low in both asthma (r = 0.19) and COPD (r = 0.24)
patients.
Predictors of Changes in FEV1 and HRQoL
The results of the longitudinal linear regression analyses,
studying the influence of different predictors on changes in
FEV1 and HRQoL, can be seen in Table 2 (univariate analy-
ses) and Table 3 (multivariate analyses). In asthma patients,
age, comorbidity, respiratory symptoms, and PEFR at base-
line were univariately associated (p < 0.20) with changes
in both FEV1 and HRQoL. In addition, level of education,
body weight, demographic region, chronic cough or spu-
tum production, and HRQoL were associated with changes
in FEV1, whereas gender, poor compliance with treatment,
duration of disease, hyperreactivity, and dyspnea were asso-
ciated with changes in HRQoL. The best predictive model
(Table 3) showed that for asthma patients, older age and
greater body weight were associated with a decline in FEV1.
Living in a suburban region (east or northwest), chronic cough
or sputum production, more frequent respiratory symptoms,
and a higher PEFR at baseline were associated with an in-
crease in FEV1. In asthma patients, older age, poor com-
pliance with treatment, more dyspnea, and a lower PEFR
were associated with a decline in HRQoL. For example, pa-
tients who were older showed a decline in FEV1 of 0.10
and a decline in HRQoL of 0.87, compared with younger
patients.
In patients with COPD, age, body weight, smoking, a posi-
tive allergy test, respiratory symptoms, and PEFR at baseline
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FIGURE 1.—FEVI1 at baseline, after one and after two years.
were univariately associated (p < 0.20) with changes in both
FEV1 and HRQoL (Table 2). In addition, demographic re-
gion, wheezing, and brochodilator use were associated with
a change in FEV1. Gender, level of educational, comorbidity,
FIGURE 2.—HRQoL at baseline, after one and after two years.
medication use, dyspnea and FEV1 were associated with
changes in HRQoL. The best predictive model (Table 3)
showed that older age, living in an urban region (west),
current smoking, and low PEFR predicted a decline in
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TABLE 2.—Predictive value of baseline patient and disease characteristics regarding changes in FEV1 and HRQoL during 2 years follow-up: results of univariate
analyses (regression coefficients (β) and 95% CI), for asthma, and COPD separately.
Asthma (n = 380) COPD (n = 120)
Characteristics
FEV1
β [95%CI]
HRQoL
β [95%CI]
FEV1
β [95%CI]
HRQoL
β [95%CI]
Gender (men) 0.95 [−0.91, 2.81] 0.60 [−0.22, 1.41]∗ −1.02 [−3.58, 1.54] 1.32 [−0.16, 2.80]∗
Age (years) −0.10 [−0.16, −0.04]∗ −0.04 [−0.07, −0.01]∗ −0.18 [−2.28, −0.08]∗ −0.06 [−0.11, 0]∗
Education level
Medium vs low 2.47 [0.54, 4.39]∗ 0.31 [−0.57, 119] 1.07 [−2.04, 4.18] 1.51 [−0.23, 3.24]∗
High vs low 0.31 [−2.32, 0.55] 0.34 [−0.74, 1.42] 1.35 [−2.90, 5.60] 1.75 [−0.61, 4.11]∗
Body weight −0.06 [−0.11, 0]∗ −0.01 [−0.04, 0.01] 0.08 [−0.01, 0.17]∗ 0.04 [−0.01, 0.09]∗
Region of livinga
East vs west 2.05 [−0.40, 4.49]∗ −0.58 [−1.69, 0.53] 4.49 [1.45, 7.53]∗ −0.13 [−1.90, 1.64]
Northwest vs west 4.58 [1.63, 7.53]∗ 0.67 [−0.42, 1.77] 3.97 [1.96, 7.94]∗ −0.98 [−3.16, 1.20]
Co-morbidity 1.32 [−3.09, 0.44]∗ −0.64 [−1.45, 0.17]∗ −1.92 [−4.39, 0.55] −0.99 [−2.39, 0.42]∗
Smoking
Former vs never −0.58 [−2.58, 1.43] −0.54 [−1.44, 0.36] −2.82 [−6.09, 0.45]∗ −1.33 [−3.20, 0.55]∗
Current vs never −0.12 [−2.30, 2.07] −0.29 [−1.27, 0.69] −5.31 [−8.62, −2.0]∗ −0.67 [−2.59, 1.26]
Medicationb
Step 2 vs step 1 −0.33 [−0.44, 1.79] −0.39 [−1.33, 0.57] 2.12 [−2.05, 6.28] −0.84 [−3.13, 1.45]
Step 3 & 4 vs step 1 −1.16 [−3.94, 1.62] −0.59 [−1.85, 0.67] 2.11 [−2.35, 6.57] −2.46 [−4.86, −0.06]∗
Compliance
Not compliant vs compliant 0.61 [−1.44, 2.65] −0.77 [−1.70, 0.16]∗ 1.67 [−1.04, 3.87] 0.22 [−1.32, 1.77]
Missing vs compliant 0.65 [−1.49, 2.78] 0.53 [−0.43, 1.48] 0.26 [−351, 4.03] 1.10 [−1.05, 3.24]
Duration of disease (years) −0.02 [−0.08, 0.04] −0.03 [−0.05, 0]∗ 0.01 [−0.05, 0.07] 0 [−0.04, 0.03]
Allergy test
Positive vs negative −0.60 [−2.41, −0.65] 0.54 [−0.27, 1.35] 1.92 [−0.72, 4.56]∗ 1.53 [0.03, 3.03]∗
Missing vs negative 1.06 [−2.65, 4.77] 0.24 [−1.46, 1.93] 2.02 [−3.49, 7.53] 0.80 [−2.30, 3.91]
Hyperreactivity 0.96 [−0.92, 2.84] −0.41 [−1.32, 0.5]∗ 0.03 [−2.54, 2.60] 0.45 [−0.84, 2.09]
Dyspnea-gradesc (score) −0.39 [−1.14, 0.37] −0.54 [−0.93, −0.14]∗ −0.12 [−1.15, 0.91] −0.78 [−1.46, −0.10]∗
Wheeze
Ever vs never −1.92 [−5.24, 5.24] 0.75 [−0.74, 2.23] 3.9 [−0.03, 7.83]∗ −0.59 [−2.85, 1.66]
Most days and nights vs never −1.28 [−0.506, 2.50] 0.98 [−0.75, 270] 2.86 [−1.64, 7.36] −1.24 [−3.85, 1.38]
Chronic cough or sputum production present 1.72 [0.01, 3.44]∗ −0.17 [−0.98, 0.64] −1.70 [−4.2, 0.8] −0.26 [−1.75, 1.20]
Days or nights disturbed by respiratory complaintsd 0.52 [0.16, 0.89]∗ −0.13 [−0.31, 0.05]∗ −0.24 [−0.61, 0.14]∗ −0.47 [−0.71, −0.22]∗
Use of β-agonistsd 0 [−0.14, 0.15] −0.06 [−0.13, 0.01]∗ −0.21 [−0.47, 0.04]∗ −0.03 [−0.18, 0.11]
PEFR (low (morning)%predicted)d 0.09 [0.04, 0.15]∗ 0.04 [0.01, 0.06]∗ 0.22 [0.13, 0.31]∗ 0.06 [0.01, 0.10]∗
FEV1 0.01 [−0.01, 0.04] 0.08 [0.03, 0.12]∗
HRQoL −0.10 [−0.25, 0.04]∗ 0.10 [−0.11, 0.31]
∗p-value < 0.20.
aRegion of living: west is urban, east and northwest are suburban.
bStepped care therapy: step 1, β-agonists only; step 2, low or moderate dose corticosteroids or cromoglycerine; step 3, moderate-dose corticosteroids or cromoglycine and long-acting
β-agonists; and step 4, high-dose corticosteroids or cromoglycine with long-acting β-agonists.
cHigher score indicates less severe dyspnea.
d Measured by day chart over a period of 14 days.
TABLE 3.—Predictive value of baseline patient and disease characteristics regarding changes in FEV1 and HRQoL during 2 years follow-up: results of multivariate
analyses (regression coefficients (β) and 95% (CI)) for asthma and COPD separately: best predicting model.
Asthma (n = 380) COPD (n = 120)
Characteristics
FEV1
β [95%CI]
HRQoL
β [95%CI]
FEV1
β [95%CI]
HRQoL
β [95%CI]
Gender (men) 2.48 [1.07, 3.89]§
Age (years) −0.10 [−0.15, −0.04]§ −0.03 [−0.06, 0]¶ −0.14 [−0.23, −0.04]§
Education level
Medium vs low 1.36 [−0.22, 2.93]
High vs low 2.09 [−0.08, 4.26]∗
Body weight (kg) −0.07 [−1.2, −0.01]¶ 0.05 [0, 0.10]¶
Region of livinga
East vs west 1.84 [−0.50, 4.17] 2.93 [0, 07, 5.79]¶
Northwest vs west 2.83 [0.04, 5.62]¶ 2.63 [−0.94, 6.20]
Smoking
Former vs never −1.81 [−4.78, 1.16]
Current vs never −2.94 [−5.99, 0.11]∗
Compliance
Not compliant vs compliant −0.87 [−1.79, 0.04]∗
Missing vs compliant 0.43 [−0.51, 1.37]
Dyspnea-gradesb −0.37 [−0.77, 0.02]∗ −0.80 [−1.43, 0.17]¶
Chronic cough or sputum production present 1.74 [0.07, 3.41]¶
Days or nights disturbed by respiratory complaintsc 0.70 [0.3, 1.06]§ −0.41 [−0.64, −0.17]§
PEFR (low (morning)%predicted)c 0.11 [0.06, 0.16]§ 0.03 [0.01, 0.06]§ 0.16 [0.06, 0.25]§
p-value: § < 0.01, ¶ < 0.05, and ∗ < 0.10.
aRegion of living: west is urban, east and northwest are suburban.
bHigher score indicates less severe dyspnea.
cMeasured by day chart over a period of 14 days.
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FEV1. Female gender, higher level of education, and greater
body weight were associated with an increase in HRQoL.
More dyspnea and more frequent respiratory symptoms
were associated with a decline in HRQoL. For exam-
ple, for every point a patient who scored lower on the
dyspnea scale, a mean decline of 0.80 was found in
HRQoL.
DISCUSSION
Both FEV1 and HRQoL were poorer in patient with COPD
than in asthma patients. Furthermore, COPD patients showed
a greater decline in FEV1 and HRQoL over a period of 2 years.
Longitudinal multivariate analyses showed different predic-
tors of changes in FEV1 and HRQoL in both asthma and
COPD patients. Older age, living in an urban area, and low
PEFR at baseline were associated with a decline in FEV1 in
both asthma and COPD patients. In patients with asthma,
a greater body weight, no chronic cough or sputum pro-
duction, and less frequent respiratory symptoms also pre-
dicted a decline in FEV1, whereas current smoking predicted
a decline in FEV1 in COPD patients. A decline in HRQoL
was in both asthma and COPD predicted by a higher de-
gree of dyspnea. Other predictors of a decline of HRQoL
in asthma patients were older age, poor compliance, and
lower PEFR, whereas in COPD patients these were male
gender, lower body weight, and more frequent respiratory
symptoms.
The Course of FEV1 and HRQoL Over a Period of 2 Years
Over a period of 2 years the mean change in FEV1 and
HRQoL in asthma patients was small. In contrast, patients
with COPD showed a significant decline in FEV1 over a pe-
riod of 2 years and a significant decline in HRQoL in the
second year. These results are in line with expectations re-
garding the course of these diseases (5, 21, 22). It might be
true that a study period of 2 years is too short to demonstrate
important mean changes in FEV1 or HRQoL, especially in
asthma patients. However, there was sufficient variation in the
changes in FEV1 and HRQoL among the patients to identify
a number of relevant predictors.
These longitudinal findings confirm previous cross-
sectional findings that respiratory symptoms are poorly asso-
ciated with objective disease parameters such as FEV1, but
more strongly associated with subjective disease parameters
such as HRQoL (1, 23). Chronic cough or sputum production
and frequent respiratory symptoms at baseline even predicted
an improvement in FEV1 in the asthma patients. However,
this finding, may very well reflect the changeable, episodic
nature of the disease and may indicate that respiratory prob-
lems disappear over time.
Predictors of Changes in FEV1 and HRQoL Over a Period
of 2 Years
In both asthma and COPD patients, more severe dyspnea at
baseline was associated with a subsequent decline in HRQoL.
Since other researchers also found a strong correlation be-
tween dyspnea and HRQoL (3, 4, 24) and dyspnea can be
easily measured in a clinical setting, it might be worthwhile
to make a standard assessment of dyspnea in clinical practice
(4, 25).
The results of previous research are inconsistent with re-
spect to the associations between PEFR and HRQoL (26). In
the present study a significant but weak association was found
between low PEFR at baseline and a decline in HRQoL. A
stronger association was found between a low mean PEFR
at baseline and a decline in FEV1 in both asthma and COPD
patients.
As expected, the results showed that smoking predicts a
stronger decline in FEV1 in COPD patients (5). Living in
an urban region (west) compared to a suburban region (east
or northwest) predicted a decline in FEV1 in both asthma
and COPD patients. A possible explanation for this result
might be a difference in the measurement conditions. How-
ever, since the same spirometer was used in the east and
the west, and the training instructions for the research as-
sistants were very similar, this is not likely. Another more
likely explanation is the difference in the grade of urbaniza-
tion. Patients living in more urbanized areas may be more
severely affected, receive less optimal treatment, or live in
poorer conditions, compared to those in suburban areas.
As far as we know, only a few studies have investigated the
change in FEV1 over time, and none have studied changes in
HRQoL in patients in a primary care. Most other studies that
investigated predictors of FEV1 and HRQoL had a cross-
sectional design (11). The strength of the present study is
that it was possible to identify predictors of changes within
patients over a period of 2 years and investigate the predictive
value of several patient and disease characteristics.
The participants in this study were patients in primary care
who used medication and had reported some respiratory com-
plaints during selection. The present study group may not be
representative for patients with even milder forms of asthma
or COPD in general practice, for well-controlled asthma pa-
tients (no symptoms), or for patients in secondary care. How-
ever, we feel that the study population does represent an av-
erage population of patients with mild to moderate asthma or
COPD in primary care.
CONCLUSION
FEV1 and HRQoL appear to be influenced by different pre-
dictors (27). This suggests that besides FEV1 measurements,
HRQoL should also be taken into account by physicians, as
this clearly reflects a different aspect of the disease. Dyspnea
seems to be an important predictor of decline in HRQoL in
both asthma and COPD patients. More research is needed
to determine whether a short dyspnea questionnaire can be
of value in routine general practice to anticipate a decline in
HRQoL in individual patients (25). Finally, a few additional
factors might help physicians to identify patients who are at
risk for a decline in FEV1 (older age, living in an urban area,
and smoking) or a decline in HRQoL (lower level of edu-
cation, poor compliance with treatment, and more frequent
respiratory complaints).
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